Opinion|Videos|July 12, 2024

Evaluating Value of BTK Inhibitors in CLL Treatment

Experts evaluate the value of BTK inhibitors in CLL treatment.

Video content above is prompted by the following question(s):

  • How are payers evaluating the value of BTK inhibitors in the evolving treatment landscape of CLL?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.


Latest CME

Brand Logo

259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo